Seek Returns

ARGX vs. PCVX: argenx vs. Vaxcyte Stock Comparison

How do argenx (ARGX) and Vaxcyte (PCVX) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

argenx (ARGX) and Vaxcyte (PCVX) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Vaxcyte (PCVX) trades as ordinary local shares, while argenx (ARGX) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Company profile comparison for argenx (ARGX) and Vaxcyte (PCVX)
Profile ItemARGXPCVX
Nameargenx SE American Depositary ReceiptVaxcyte Inc.
Country/RegionNetherlandsUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyBiotechnology
GICS Sub-IndustryBiotechnologyBiotechnology
Market Capitalization58.31 billion USD10.11 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateMay 18, 2017June 12, 2020
Security TypeADRCommon Stock

Price Performance

Cumulative Growth

ARGX
PCVX
GSPC
Loading price history…
argenx (ARGX) vs. Vaxcyte (PCVX), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for argenx (ARGX) and Vaxcyte (PCVX). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for argenx (ARGX) and Vaxcyte (PCVX). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for argenx (ARGX) and Vaxcyte (PCVX)
MetricARGXPCVX
Total Return (1Y)11.91%59.00%
Total Return (3Y, Annualized)25.68%11.29%
Total Return (5Y, Annualized)24.22%21.60%

Risk Profile

Drawdown History

ARGX
PCVX
GSPC
Loading price history…
argenx (ARGX) vs. Vaxcyte (PCVX), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for argenx (ARGX) and Vaxcyte (PCVX). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for argenx (ARGX) and Vaxcyte (PCVX)
MetricARGXPCVX
Volatility (1Y, Annualized)37.87%56.01%
Beta (5Y)0.451.26
Max Drawdown (5Y)-38.20%-76.22%
Avg. Volume (3M)359.84K2.12M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
ARGX and PCVX are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for argenx (ARGX) and Vaxcyte (PCVX)
MetricARGXPCVX
Sharpe Ratio (1Y)0.200.98
Sortino Ratio (1Y)0.311.76

Profitability

ROE (TTM)

argenx (ARGX) has no ROE value reported for this period; Vaxcyte (PCVX) reports a negative figure of -42.68%, which needs context because negative ROE can reflect losses or negative shareholders’ equity.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
109.18%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
ARGX
--

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

-42.68%

Max
109.18%
Q3
6.23%
Median
-26.66%
PCVX
-42.68%
Q1
-64.05%
Min
-167.77%
Loading chart…
argenx (ARGX) vs. Vaxcyte (PCVX): ARGX does not report ROE, so it has no value marker; PCVX is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Net Margin (TTM)

argenx (ARGX) at 31.73% converts revenue to bottom-line profit above its industry’s benchmark range, while Vaxcyte (PCVX) at 0.00% keeps roughly the typical share for its industry.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

31.73%

ARGX
31.73%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max
18.05%
Q3
4.78%
PCVX
0.00%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
argenx (ARGX) vs. Vaxcyte (PCVX): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

argenx (ARGX) at 36.27% operates in the top operating margin quartile, ahead of Vaxcyte (PCVX) at 0.00%, which runs around its industry’s norm.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

36.27%

Max
83.12%
ARGX
36.27%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max
83.12%
Q3
14.77%
PCVX
0.00%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
argenx (ARGX) vs. Vaxcyte (PCVX): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for argenx (ARGX) and Vaxcyte (PCVX)
MetricARGXPCVX
ROE (TTM)---42.68%
ROA (TTM)---24.98%
Net Margin (TTM)31.73%0.00%
Operating Margin (TTM)36.27%0.00%
Gross Margin (TTM)59.84%0.00%

Growth

Revenue Growth

Only one side can be read here: argenx (ARGX) reports revenue growth of 89.64%, ranked against its industry; Vaxcyte (PCVX) has no revenue growth figure this period.

Loading chart…
argenx (ARGX) vs. Vaxcyte (PCVX): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: argenx (ARGX) reports EPS growth of 53.13%, ranked against its industry; Vaxcyte (PCVX) has no EPS growth figure this period.

Loading chart…
argenx (ARGX) vs. Vaxcyte (PCVX): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for argenx (ARGX) and Vaxcyte (PCVX)
MetricARGXPCVX
Revenue Growth (YoY)89.64%--
Revenue Growth (3Y CAGR)116.25%--
EPS Growth (YoY)53.13%--
EPS Growth (3Y CAGR)----

Financial Strength

Current Ratio (MRQ)

Short-term liquidity can only be read on one side of this pairing: Vaxcyte (PCVX) shows current ratio of 4.56 against its industry benchmark, while argenx (ARGX) has no reading this period.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
Min
0.10
ARGX
--

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.56

Max
25.13
Q3
12.13
Median
5.52
PCVX
4.56
Q1
2.47
Min
0.10
Loading chart…
argenx (ARGX) vs. Vaxcyte (PCVX): ARGX does not report current ratio, so it has no value marker; PCVX is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Debt / Equity (MRQ)

argenx (ARGX) at 0.01 keeps leverage in the lower industry quartile, while Vaxcyte (PCVX) at 0.09 runs a more typical debt-to-equity mix.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.01

Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
ARGX
0.01
Min
0.00

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.09

Max
1.42
Q3
0.65
Median
0.15
PCVX
0.09
Q1
0.02
Min
0.00
Loading chart…
argenx (ARGX) vs. Vaxcyte (PCVX): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for argenx (ARGX) and Vaxcyte (PCVX)
MetricARGXPCVX
Current Ratio (MRQ)--4.56
Debt / Equity (MRQ)0.010.09
Net Debt / EBITDA-2.70--

Dividends

Dividend Yield (TTM)

Neither argenx (ARGX) nor Vaxcyte (PCVX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ARGX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

PCVX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
argenx (ARGX) vs. Vaxcyte (PCVX): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither argenx (ARGX) nor Vaxcyte (PCVX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ARGX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

PCVX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
argenx (ARGX) vs. Vaxcyte (PCVX): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for argenx (ARGX) and Vaxcyte (PCVX)
MetricARGXPCVX
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: argenx (ARGX) trades at 32.12 times trailing earnings, ranked against its peers, while Vaxcyte (PCVX) has no P/E ratio this period.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

32.12

Max
85.34
Q3
43.46
ARGX
32.12
Median
26.69
Q1
13.30
Min
0.07

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
PCVX
--
Loading chart…
argenx (ARGX) vs. Vaxcyte (PCVX): PCVX does not report P/E ratio, so it has no value marker; ARGX is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

A sales-based read is only available for argenx (ARGX), whose P/S ratio of 9.86 ranks against industry peers; Vaxcyte (PCVX) reports no figure this period.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.86

Max
58.18
Q3
25.77
ARGX
9.86
Median
7.30
Q1
3.01
Min
0.01

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
Min
0.01
PCVX
--
Loading chart…
argenx (ARGX) vs. Vaxcyte (PCVX): PCVX does not report P/S ratio, so it has no value marker; ARGX is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/B Ratio (MRQ)

Vaxcyte (PCVX) at 3.83 sits near its industry’s typical P/B ratio, while argenx (ARGX) at 172.23 prices above its benchmark range — ARGX looks rich relative to book.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

172.23

ARGX
172.23
Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.83

Max
13.53
Q3
6.54
PCVX
3.83
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
argenx (ARGX) vs. Vaxcyte (PCVX): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for argenx (ARGX) and Vaxcyte (PCVX)
MetricARGXPCVX
P/E Ratio (TTM)32.12--
P/S Ratio (TTM)9.86--
P/B Ratio (MRQ)172.233.83
Free Cash Flow Yield (TTM)---5.24%